Comparative Pharmacology
Head-to-head clinical analysis: STROMECTOL versus VERMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STROMECTOL versus VERMOX.
STROMECTOL vs VERMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ivermectin acts by binding selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions, hyperpolarization of nerve or muscle cells, and death of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA).
Binds to β-tubulin in parasitic cells, inhibiting microtubule polymerization, thereby impairing glucose uptake and causing energy depletion and parasite death.
Oral: 200 mcg/kg once daily for 1-2 days. For strongyloidiasis, 200 mcg/kg/day for 2 days. For onchocerciasis, single dose of 150 mcg/kg.
Mebendazole 100 mg orally twice daily for 3 days for pinworm, whipworm, hookworm, and roundworm infections. For pinworm, may repeat after 2 weeks. For hookworm and whipworm, may require longer courses.
None Documented
None Documented
Terminal elimination half-life is approximately 18 hours (range 10–30 hours) in healthy subjects; prolonged in hepatic impairment.
2-8 hours (terminal half-life, may be prolonged in hepatic impairment or obstruction)
Primarily fecal (90%) as unchanged drug and metabolites; renal excretion accounts for <1% of the dose.
Fecal (90%) as unchanged drug and metabolites; renal (<10%)
Category C
Category C
Anthelmintic
Anthelmintic